Cvrx, Inc. - CVRX STOCK NEWS

CVRx (NASDAQ: CVRX) announced preliminary Q1 2025 revenue of approximately $12.3 million, showing 15% growth compared to Q1 2024's $10.8 million. The revenue comprises $11.2 million from U.S. operations and $1.1 million from European operations.

Despite growth, revenue fell short of expectations due to seasonal softness and newer sales representatives still developing their territories. The company's U.S. presence includes 227 active implanting centers, up from 223 in December 2024, while sales territories decreased by 3 to 45.

The company's cash position stands at $102.7 million. During Q1 2025, CVRx issued 543,462 shares through an at-the-market offering, raising $9.5 million in gross proceeds.

CVRx (NASDAQ: CVRX) presented new real-world evidence at THT 2025 demonstrating significant reductions in healthcare utilization with Barostim for heart failure patients. The study, published in the Journal of Cardiac Failure, analyzed data from 306 Barostim patients using the Premier Healthcare Database.

The analysis compared 12 months pre-implant data with almost two years post-implant (1.92±1.87 years), revealing remarkable reductions in hospital visits:

• 86% reduction in all-cause hospital visits
• 84% reduction in cardiovascular hospital visits
• 85% reduction in heart-failure hospital visits

CVRx reported strong financial results for Q4 and full year 2024. Q4 revenue reached $15.3 million, up 36% year-over-year, driven by a 41% increase in U.S. Heart Failure revenue to $14.3 million. Full-year 2024 revenue was $51.3 million, showing 31% growth from 2023.

Active implanting centers increased 25% to 223, and U.S. sales territories expanded to 48. Despite revenue growth, the company reported a Q4 net loss of $10.7 million ($0.43 per share) and a full-year net loss of $60.0 million ($2.65 per share). The company raised $33.8 million through share offerings in 2024.

Looking ahead to 2025, CVRx projects total revenue between $63.0-65.0 million, with gross margins of 83-84%. Q1 2025 revenue is expected between $14.5-15.0 million.

CVRx (NASDAQ: CVRX), a commercial-stage medical device company specializing in Barostim™, an innovative extravascular neuromodulation device for cardiovascular diseases, has announced its plans to release fourth quarter 2024 financial and operating results after market close on Tuesday, February 4, 2025.

The company will host a conference call and webcast at 4:30pm Eastern Time on the same day to review the results. Investors can access the webcast through the company's investor relations website at ir.cvrx.com. For telephone access, U.S. callers can dial 1-877-704-4453, while international callers should use 1-201-389-0920.

CVRx, a commercial-stage medical device company, announced preliminary unaudited fourth quarter and full year 2024 revenue results, along with its 2025 business outlook.

Fourth quarter revenue is expected to be between $15.2 million and $15.3 million, marking a 35% increase from the previous year's $11.3 million. Full year 2024 revenue is projected to be between $51.1 million and $51.2 million, a 30% increase from 2023's $39.3 million. U.S. revenue for 2024 is expected to be between $47.0 million and $47.1 million, with European revenue at $4.1 million.

For 2025, CVRx forecasts revenue between $63.0 million and $65.0 million, representing a 23% to 27% growth. The company also expects gross margins of 83%-84% and operating expenses between $100.0 million and $104.0 million. First-quarter 2025 revenue is anticipated to be between $14.5 million and $15.0 million.

Notably, the company saw a 41% increase in U.S. heart failure revenue in Q4 2024 and expanded its active implanting centers in the U.S. to 223 by the end of 2024. Additionally, CVRx raised $12.8 million in gross proceeds through its at-the-market offering, increasing its cash and cash equivalents to $105.9 million as of December 31, 2024.

CVRx (NASDAQ: CVRX), a commercial-stage medical device company, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. The company's management team is scheduled to deliver a presentation on Wednesday, January 15, 2025, at 2:15 PM Pacific Time. Interested parties can access a live audio webcast of the presentation through the investor relations section of CVRx's website at ir.cvrx.com.

CVRx (NASDAQ: CVRX) has announced its upcoming participation in the Piper Sandler 36th Annual Healthcare Conference. The medical device company's management team is scheduled to deliver a presentation on Wednesday, December 4, 2024, at 3:30 PM Eastern Time. Interested parties can access a live audio webcast of the presentation through the investor relations section of CVRx's website at ir.cvrx.com.

CVRx announced that CMS has assigned the Barostim procedure to New Technology APC 1580, maintaining the outpatient payment of approximately $45,000 in 2025. This follows two other positive reimbursement developments: the transition to Category I CPT codes in 2026 and the reassignment to a higher-paying MS-DRG for inpatient procedures, increasing payment from $17,000-$23,000 to $43,000, effective October 2024. These changes aim to improve patient access to Barostim therapy and strengthen the company's commercial foundation.

CVRx reported strong Q3 2024 results with total revenue of $13.4 million, up 27% year-over-year. U.S. Heart Failure revenue reached $12.2 million, increasing 30%. Active implanting centers grew to 208, up 31%. The company achieved significant milestones including Barostim's reassignment to MS-DRG 276, increasing hospital payments from $17,000-$23,000 to approximately $43,000, and securing Category I CPT codes effective January 2026. However, net loss widened to $13.1 million ($0.57 per share) compared to $9.0 million in Q3 2023. The company narrowed its 2024 revenue guidance to $50.5-$51.5 million.